SIPO rejects Gilead’s Sovaldi patent application

23-06-2015

SIPO rejects Gilead’s Sovaldi patent application

Daniel Fung / Shutterstock.com

China’s State Intellectual Property Office (SIPO) has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.


Gilead; Sovaldi; Initiative for Medicines, Access & Knowledge; I-MAK; patent application; generic versions; hepatitis C

LSIPR